Hormone therapy (HT) in women with gynecologic cancers and in women at high risk for developing a gynecologic cancer: A Society of Gynecologic Oncology (SGO) clinical practice statement
- 1 May 2020
- journal article
- research article
- Published by Elsevier in Gynecologic Oncology
- Vol. 157 (2) , 303-306
Abstract
No abstract availableThis publication has 46 references indexed in Scilit:
- Expression of steroid and xenobiotic receptor in uterine carcinosarcoma, leiomyosarcoma and endometrial stromal sarcomaOncology Letters, 2013
- Hormone replacement therapy in gynecologic cancer survivors: Why not?Gynecologic Oncology, 2011
- Estrogen replacement therapy after endometrial cancer: a survey of physicians' prescribing practiceClimacteric, 2010
- Endometrial effects of a tissue selective estrogen complex containing bazedoxifene/conjugated estrogens as a menopausal therapyFertility and Sterility, 2009
- Use of hormone replacement therapy before and after ovarian cancer diagnosis and ovarian cancer survivalInternational Journal of Cancer, 2006
- Hormone replacement therapy and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriersGynecologic Oncology, 2006
- Effects of Conjugated Equine Estrogen in Postmenopausal Women With HysterectomyJAMA, 2004
- Hormone replacement therapy after invasive ovarian serous cystadenocarcinoma treatment: the effect on survivalMenopause, 2001
- Estrogen replacement therapy for ovarian carcinoma survivorsCancer, 1999
- Incidence of ovarian metastasis in patients with cancer of the uterine cervixGynecologic Oncology, 1987